SITC | Conference

Ipilimumab Plus Nivolumab Promising for Patients with Metastatic or Unresectable Angiosarcoma
November 21, 2020

A study presented at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting suggested that ipilimumab (Yervoy) plus nivolumab (Opdivo) for patients with metastatic or unresectable angiosarcoma was well-tolerated.

Tavokinogene Telseplasmid, Pembrolizumab Combo Promising in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
November 10, 2020

“The data reported, in addition to its ease of use, demonstrate the potential of [tavokinogene telseplasmid] in combination with pembrolizumab as a next-generation intratumoral IL-12 therapy that can induce regression of both locally treated and untreated distant and visceral lesions,” said Paolo A. Ascierto, MD.

Marjorie Zauderer, MD, on New Immunotherapy Approaches
November 15, 2019

Marjorie Zauderer, MD, from Memorial Sloan Kettering Cancer Center, discussed new immunotherapy approaches at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).